144 Financial Statements 14 Interest-bearing loans and borrowings Repayment 2009 2008 2007 dates $m $m $m Current liabilities Bank overdrafts On demand 90 163 140 Floating rate note US dollars 2009 650 4.625% Non-callable bond Euros 2010 1,073 5.625% Non-callable bond Euros 2010 717 Other loans Within one year 46 180 4,140 1,926 993 4,280 Non-current liabilities Floating rate note US dollars 2009 649 4.625% Non-callable bond Euros 2010 1,053 1,099 5.625% Non-callable bond Euros 2010 702 5.4% Callable bond US dollars 2012 1,805 1,823 1,765 5.4% Callable bond US dollars 2014 821 789 767 5.125% Non-callable bond Euros 2015 1,072 1,051 1,099 5.9% Callable bond US dollars 2017 1,818 1,896 1,768 7% Guaranteed debentures US dollars 2023 346 324 323 5.75% Non-callable bond Pounds sterling 2031 558 501 691 6.45% Callable bond US dollars 2037 2,717 2,716 2,715 9,137 10,855 10,876 All loans and borrowings above are unsecured.
15 Financial risk management objectives and policies The Groups principal financial instruments, other than derivatives, comprise bank overdrafts, loans, current and non-current investments, cash and short-term deposits.
The main purpose of these financial instruments is to manage the Groups funding and liquidity requirements.
The Group has other financial assets and liabilities such as trade receivables and trade payables, which arise directly from its operations.
The principal financial risks to which the Group is exposed are those of liquidity, interest rate, foreign currency and credit.
Each of these is managed in accordance with Board-approved policies.
These policies are set out below.
The Group uses foreign currency borrowings, foreign currency forwards and options, interest rate swaps and forward rate agreements for the purpose of hedging its foreign currency and interest rate risks.
The Group may designate certain financial instruments as either fair-value hedges or net investment hedges in accordance with IAS 39.
Key controls applied to transactions in derivative financial instruments are: to use only instruments where good market liquidity exists, to revalue all financial instruments regularly using current market rates and to sell options only to offset previously purchased options.
The Group does not use derivative financial instruments for speculative purposes.
Capital management The capital structure of the Group consists of shareholders equity Note 20, debt Note 14 and cash Note 13.
For the foreseeable future, the Board will maintain a capital structure that supports the Groups strategic objectives through: Managing funding and liquidity risk.
Maintaining a strong investment-grade credit rating.
Funding and liquidity risk are reviewed regularly by the Board and managed in accordance with policies described below.
The Boards distribution policy comprises both a regular cash dividend and subject to business needs, a share re-purchase component.
The Board regularly reviews its shareholders return strategy, and in 2009 adopted a progressive dividend policy, whereby the Board intends to maintain or grow the dividend each year, targeting an average dividend cover of 2 times ie a payout ratio of 50%, based on reported earnings, before restructuring costs.
In addition, after providing for business investment, funding the progressive dividend policy and meeting debt service obligations, the Board will regularly assess the opportunity to return cash in excess of these requirements to shareholders through share re-purchases.
The Groups net debt position loans and borrowings net of cash and cash equivalents, current investments and derivative financial instruments has reduced from $7,174m at the beginning of the year to a net funds position of $535m at 31 December 2009 as a result of strong net operating cash in flows.
The Groups policy is to manage its debt level so as to maintain a strong investment-grade credit rating.
The Groups current long-term credit rating is A1 by Moodys and AAby Standard and Poors, both with a stable outlook.
AstraZeneca Annual Report and Form 20-F Information 2009
